IN BRIEF: Oxford BioDynamics Annual Revenue Hurt By Covid-19 Pandemic
IN BRIEF: Oxford BioDynamics Annual Revenue Hurt By Covid-19 Pandemic Thu, 28th Jan 2021 20:25 Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic biomarkers - Says 2020 was a year of transition and development with company readying for near-term commercialisation of its 3D genomics technology platform, EpiSwitch. Says R&D project revenues were affected by the Covid-19 pandemic. For year ended September 30, posts revenue of GBP456,000 down from GBP907,000 as pretax loss widens to GBP4.9 million from GBP3.4 million. Chief Executive Officer Jon Burrow...
Source: lse.co.uk